Introduction
============

Prostate cancer is one of the most common malignancies in Western males, which accounts for 9% of death in males, and the second leading cause of male cancer-related death.[@b1-cmar-10-3599] The standard treatment for advanced or metastatic prostate cancer is androgen deprivation therapy (ADT).[@b2-cmar-10-3599] Despite the high response rate of ADT, most prostate cancer patients progressed gradually and irreversibly to castration-resistant prostate cancer (CRPC).[@b3-cmar-10-3599] Docetaxel, the first-line use of chemotherapeutic agents to treat patients with CRPC, has been shown to confer a survival benefit in patients with CRPC.[@b4-cmar-10-3599],[@b5-cmar-10-3599] Several other agents, including cabazitaxel (CBZ),[@b6-cmar-10-3599] enzalutamide (ENZ),[@b7-cmar-10-3599],[@b8-cmar-10-3599] abiraterone acetate (AA),[@b9-cmar-10-3599],[@b10-cmar-10-3599] radium-223,[@b11-cmar-10-3599] and sipuleucel-T,[@b12-cmar-10-3599] also have been shown to confer a survival benefit in patients with metastatic CRPC (mCRPC). Although some prognostic factors and biomarkers have been reported, a more proper predictive and prognostic biomarker is required to predict the response of patients with CRPC-received chemotherapy accurately.

Cancer-related inflammatory response plays an important role in the progression of cancer development.[@b13-cmar-10-3599],[@b14-cmar-10-3599] Neutrophil-to-lymphocyte ratio (NLR), a marker of the systemic inflammatory response that can be easily measured from routine complete blood counts (CBCs) in the peripheral blood, has been reported to be an independent prognostic factor in cancers.[@b15-cmar-10-3599]--[@b18-cmar-10-3599] NLR has shown to predict poor survival of patient with localized prostate cancer and CRPC.[@b19-cmar-10-3599]--[@b24-cmar-10-3599] However, the results of these studies for the prognostic value of NLR are inconsistent. We conducted a comprehensive meta-analysis to drive a more precise estimate of the prognostic value of the NLR in patients with CRPC.

Materials and methods
=====================

Literature search
-----------------

We comprehensively searched PubMed, Embase, Web of Science, and the Cochrane electronic databases for studies published before November 17, 2017. The search strategy combined key terms related to "castration resistant prostate cancer" or "hormone-refractory prostate cancer" or "androgen independent prostate cancer" or "metastatic prostate cancer" and "Neutrophil to Lymphocyte Ratio" or "NLR" and "prognosis" or "survival" or "outcome" in humans. Two reviewers (ZW and SP) independently screened the titles and abstracts of all initially identified studies according to the selection criteria. Full-text articles of studies that met the following selection criteria were retrieved.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria for publication selection were as follows: 1) retrospective studies on the value of NLR in predicting prognosis in castration-resistant prostate cancer patients; 2) the HRs and their 95% CIs for overall survival (OS) or progression-free survival (PFS) analysis were reported in text or could be computed from given data; 3) the value of NLR was obtained for blood sample testing; 4) defined the cutoff value of increased NLR. When multiple reports describing the same population were published, the most recent or complete report was used.

The major exclusion criteria were as follows: abstract, review, case report or comment letter; laboratory studies; animal studies; duplicate publications; published not in English.

Data extraction and quality
---------------------------

Two investigators (ZW and SP) independently extracted data, and a consensus was reached in case of any inconsistency with the involvement of a third author (HX). The following data were extracted from the eligible studies: first author, year of publication, country of origin, median age (range), treatment, median follow-up time, number of elevated NLR, cutoff value, and HR for survival (OS and/or PFS). For articles that only provided survival data in a Kaplan--Meier curve, software designed by Jayne F Tierney and Matthew R Sydes was used to digitize and extract the relative risk and its 95% CI.[@b25-cmar-10-3599]

Statistical analysis
--------------------

Data were analyzed using Stata SE12.0 (StataCorp LP, College Station, TX, USA). HR with a 95% CI was selected as the effect to measure prognostic outcomes. Study heterogeneity was evaluated using the chi-squared test and *I*[@b2-cmar-10-3599] statistic (100%×\[(*Q*--df)/*Q*\]),[@b26-cmar-10-3599],[@b27-cmar-10-3599] the value of *P*~heterogeneity~\<0.1 and *I*[@b2-cmar-10-3599]\>50% represents significant heterogeneity. The fixed-effects model was used when the value of *P*~heterogeneity~ \>0.1 and *I*[@b2-cmar-10-3599]\<50%, otherwise the random-effects model was applied. Subgroup analysis was performed for OS and PFS analysis. Begg's funnel plot and Egger's linear regression test were used to evaluate the potential for publication bias. Two-tailed *P*-value \<0.05 was considered statistically significant.

Results
=======

Features of included studies
----------------------------

The selection process for this study is shown in [Figure 1](#f1-cmar-10-3599){ref-type="fig"}. Through systematic literature searching, a total of 190 potentially relevant studies were identified. Overall, 94 duplicated articles were removed. 61 articles were excluded after screening titles and abstracts, including reviews, letters, meeting abstracts, laboratory studies, and other articles irrelevant to our study. After assessing the full text, 19 additional articles were excluded. Finally, 16 retrospective studies were included in the following meta-analysis.

Summary characteristics of these eligible studies are shown in [Table 1](#t1-cmar-10-3599){ref-type="table"}. The 16 selected studies (17 cohorts) published between 2013 and 2017 were included in the meta-analysis.[@b21-cmar-10-3599]--[@b24-cmar-10-3599],[@b28-cmar-10-3599]--[@b39-cmar-10-3599] The sample size ranged from 33 to 1,224 patients, and a total of 5,705 patients were included. All trials were conducted in adult patients with CRPC. Three studies were conducted in Asian countries (Japan[@b24-cmar-10-3599],[@b30-cmar-10-3599] and China[@b35-cmar-10-3599]). Thirteen studies were conducted in non-Asian countries, including Italy,[@b34-cmar-10-3599],[@b36-cmar-10-3599],[@b39-cmar-10-3599] UK,[@b19-cmar-10-3599],[@b23-cmar-10-3599] Australia,[@b29-cmar-10-3599],[@b31-cmar-10-3599] Germany,[@b21-cmar-10-3599],[@b22-cmar-10-3599] USA,[@b37-cmar-10-3599] Turkey,[@b33-cmar-10-3599] Canada,[@b38-cmar-10-3599] and the Netherlands.[@b32-cmar-10-3599] The NLR cutoff value ranged from 2.1 to 5. For the prognostic indicator of NLR in CRPC patients, six articles reported both OS and PFS, nine (10 cohorts) articles reported OS, and one article reported PFS.

Survival outcome
----------------

The relationship between cancer prognosis and NLR was detected in the included studies. OS and PFS were quantitatively synthesized. OS values were available from 16 cohorts with 5,571 patients with CRPC. The elevated NLR was significantly associated with poor OS (HR=1.52, 95% CI: 1.41--1.63, *P*\<0.001; I[@b2-cmar-10-3599]=37.7%, *P*~heterogeneity=0.07~; [Table 2](#t2-cmar-10-3599){ref-type="table"}, [Figure 2](#f2-cmar-10-3599){ref-type="fig"}), which meant that patients with a higher NLR had a greater mortality risk than those with a low NLR. Seven studies with 642 patients evaluated PFS outcome. The pooled results favored the patients with low NLR (HR=1.50, 95% CI: 1.21--1.85, *P*\<0.001; I[@b2-cmar-10-3599]=0.0%, *P*~heterogeneity\ =0.507~).

Subgroup analysis
-----------------

Subgroup analysis for OS and PFS was performed according to the cutoff value of NLR, nation, and treatment ([Figures 3](#f3-cmar-10-3599){ref-type="fig"} and [4](#f4-cmar-10-3599){ref-type="fig"}; [Table 2](#t2-cmar-10-3599){ref-type="table"}).

The pooled results showed that elevated NLR predicted worse OS in Asian studies (HR=2.43, 95% CI: 1.47--4.01, *P*\<0.001; [Table 2](#t2-cmar-10-3599){ref-type="table"}, [Figure 3B](#f3-cmar-10-3599){ref-type="fig"}) and second-line treatment studies (HR=1.97, 95% CI: 1.51--2.57, *P*\<0.001; [Table 2](#t2-cmar-10-3599){ref-type="table"}, [Figure 3C](#f3-cmar-10-3599){ref-type="fig"}). For PFS, elevated NLR predicted worse prognosis in cutoff value \>3.3 studies (HR=1.87, 95% CI: 1.38--2.54, *P*\<0.001; [Table 2](#t2-cmar-10-3599){ref-type="table"}, [Figure 4A](#f4-cmar-10-3599){ref-type="fig"}) and Asian studies (HR=1.99, 95% CI: 1.30--3.06, *P*=0.002; [Table 2](#t2-cmar-10-3599){ref-type="table"}, [Figure 4B](#f4-cmar-10-3599){ref-type="fig"}).

Publication bias
----------------

The publication bias in the meta-analysis was assessed by Begg's funnel plots. Funnel plots for meta-analysis of elevated NLR and OS and PFS are shown in [Figure 5](#f5-cmar-10-3599){ref-type="fig"}. The Begg's funnel plot test (OS: *P*=0.096, PFS: *P*=0.230; [Figure 5](#f5-cmar-10-3599){ref-type="fig"}) verified that there was no obvious publication bias.

Sensitivity analysis
--------------------

To evaluate the stability of the pooled results, a sensitivity analysis was performed. The result of the sensitivity analysis showed that for OS and PFS, the pooled result did not tend to exhibit alterations when an individual study was excluded ([Figure 6](#f6-cmar-10-3599){ref-type="fig"}).

Discussion
==========

The incidence of prostate cancer has been increasing in the past few years.[@b40-cmar-10-3599] Most of the prostate cancer patients progressed to CRPC eventually.[@b3-cmar-10-3599] Several chemotherapeutic agents, including docetaxel, CBZ, ENZ, and AA, have been shown to confer a survival benefit in patients with mCRPC. A more proper predictive and prognostic biomarker is required to predict the response of patients with CRPC-received chemotherapy accurately. It is reported that inflammatory status is associated with the progression of cancer development.[@b13-cmar-10-3599],[@b14-cmar-10-3599] The marker of the systemic inflammatory response, NLR, suggests an independent prognostic factor in cancers.[@b15-cmar-10-3599]--[@b18-cmar-10-3599] NLR has shown to predict poor survival in patients with CRPC. In this meta-analysis, we included 5,705 patients from 16 selected studies (17 cohorts) to evaluate the prognostic role of the NLR in CRPC patients. The pooled results indicated that an elevated NLR is an independent predictor of poor prognosis in CRPC patients.

According to the subgroup analysis, an NLR cutoff value \>3.3 had a more significant prognostic value than a cutoff value \<3.3 ([Table 2](#t2-cmar-10-3599){ref-type="table"}), which indicated that a higher NLR cutoff is more specific to predict a poor prognosis in patients with CRPC. An elevated NLR in Asian group had a more significant prognostic value than that in non-Asian group, indicating that a higher NLR is more specific to predict a poor prognosis in Asian patients with CRPC. Given the limited number of the eligible studies in the meta-analysis, although the pooled results showed that an elevated NLR is associated with a poor prognosis, it will need further investigation to identify that NLR can serve as a clinical marker of prognosis in CRPC patients.

The heterogeneity was relatively small in the included studies. It may be partially explained by nation, sample size, cutoff value, and treatment. And the subgroup analysis showed that the prognostic value of NLR was not affected by the factors included in the analysis. The sensitivity analysis also indicated that the pooled results were relatively conclusive.

Both increased neutrophil-dependent systemic inflammatory response and a lower lymphocyte-mediated antitumor immune response will lead to an elevated NLR.[@b41-cmar-10-3599],[@b42-cmar-10-3599] As a predominant leukocyte subset in human peripheral blood, neutrophils play an important role in tumor progression.[@b43-cmar-10-3599] In comparison, lymphocytes are critical components of antitumor immunity.[@b44-cmar-10-3599],[@b45-cmar-10-3599] NLR is an indicator of systemic inflammatory and immune response of the host; it is also associated with the progression of cancers.[@b15-cmar-10-3599]--[@b18-cmar-10-3599] NLR can be easily measured from routine CBCs in the peripheral blood, which is low cost, convenient, and reproducible. Moreover, NLR is closely related to the prognosis of CRPC. These reasons indicate that NLR could serve as a prognostic marker for patients with CRPC.

Several meta-analyses have been conducted on the prognosis of NLR for localized prostate cancer and mCRPC; however, the studies included in their meta-analysis were relatively small and the heterogeneity were high.[@b46-cmar-10-3599]--[@b48-cmar-10-3599] We conducted a comprehensive meta-analysis for the prognostic value of NLR for CRPC, which included 5,705 patients from 16 selected studies (17 cohorts); the pooled results indicated that an elevated NLR is an independent predictor of poor prognosis in patients with CRPC.

Limitations
===========

Several limitations should be acknowledged in the meta- analysis. First, the NLR cutoff value differed among the included studies, potential heterogeneity may exist. Therefore, more studies are required to identify the most suitable NLR cutoff value. Second, NLR could be affected by other diseases, such as inflammatory diseases, infection, renal diseases, and liver diseases.[@b49-cmar-10-3599],[@b50-cmar-10-3599] Third, the number of eligible studies in the meta-analysis is relatively small. Finally, studies with positive results are potentially more likely published than work with negative results, which could cause publication bias.[@b51-cmar-10-3599]

Conclusion
==========

Our analysis on the currently available clinical evidence suggests that elevated NLR predicted a poor OS and PFS in patients with CRPC. The NLR could serve as an indicator of the efficacy of the treatment of CRPC.
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###### 

Main characteristics of the included studies

  Authors                                Year         Duration                 Country           No. of patients     Median age (range) (years)                                Treatment                       Median follow-up (months)   NLR(+) No. (%)   NLR cutoff value   Survival analysis
  -------------------------------------- ------------ ------------------------ ----------------- ------------------- --------------------------------------------------------- ------------------------------- --------------------------- ---------------- ------------------ -------------------
  Linton et al[@b29-cmar-10-3599]        2013                                  Australia         182                 NA                                                        Docetaxel                       NA                          104 (56.5%)      ≥5                 OS
  Nuhn et al[@b21-cmar-10-3599]          2014         1998-2010                Germany           238                 68.3 (44.6-84.5)                                          Docetaxel                       15.0 (1.5-90.2)             168 (70%)        \>3                OS
  Sonpavde et al[@b37-cmar-10-3599]      2014         2008-2010                USA               848                 68 (NA)                                                   Docetaxel                       NA                          NA               \>3.4              OS
  Sümbül et al[@b33-cmar-10-3599]        2014         2009-2013                Turkey            33                  71.24[\*](#tfn1-cmar-10-3599){ref-type="table-fn"} (NA)   Docetaxel                       NA                          18(54.6%)        \>3                PFS
  Templeton et al[@b38-cmar-10-3599]     2014         2001-2011                Canada            357                 71 (44-90)                                                Docetaxel                       NA                          260 (73%)        \>3                OS
  Lorente et al[@b19-cmar-10-3599]       2015         NA                       UK                755                 67 (62-73)                                                Docetaxel or mitoxantrone       NA                          NA               \>3                OS
  McLachlan et al[@b31-cmar-10-3599]     2015         2005-2012                Australia         42                  (50-84)                                                   Docetaxel or Cabazitaxel        NA                          14(33.3%)        ≥5                 OS. PFS
  van Soest et al[@b32-cmar-10-3599]     2015         NA                       The Netherlands   1,224               68 (40-88)                                                VENICE (Docetaxel)              NA                          NA               ≥2                 OS
  1,006                                  68 (36-92)   TAX327 (D3+ Docetaxel)   NA                NA                  ≥2.1                                                      OS                                                                                              
  Yao et al[@b30-cmar-10-3599]           2015         2009-2014                Japan             57                  74.0 (55-91)                                              Docetaxel                       19.0(1-61)                  27 (47.4%)       ≥3.5               OS. PFS
  Conteduca et al[@b34-cmar-10-3599]     2016         2012-2014                Italy             [1]{.smallcaps}93   73.1 (42.8-90.7)                                          Enzalutamide                    10.4 (NA)                   105 (54.4%)      \>3                OS. PFS
  Lolli et al[@b39-cmar-10-3599]         2016         2011-2015                Italy             230                 74 (45-90)                                                Abiraterone                     29 (1-55)                   104 (45.2%)      ≥3                 OS
  Boegemann et al[@b22-cmar-10-3599]     2017         NA                       Germany           96                  70 (NA)                                                   Abiraterone                     22 (NA)                     17(17.7%)        \>5                OS. PFS
  Buttigliero et al[@b36-cmar-10-3599]   2017         2004-2016                Italy             110                 68 (48-85)                                                Docetaxel                       31.7 (NA)                   64 (58%)         \>3                OS. PFS
  Mehra et al[@b23-cmar-10-3599]         2017         NA                       UK                75                  NA                                                        Prednisolone or dexamethasone   NA                          NA               ≥2.6               OS
  Pei et al[@b35-cmar-10-3599]           2017         2009-2016                China             111                 71(43-86)                                                 Docetaxel                       16 (1-50)                   42 (37.8%)       \>3.3              OS. PFS
  Uemura et al[@b24-cmar-10-3599]        2017         2014-2016                Japan             47                  NA                                                        Cabazitaxel                     NA                          20 (42.6%)       ≥3.83              OS

**Note:**

mean age.

**Abbreviations:** NA, not available; NLR, neutrophil--lymphocyte ratio; OS, overall survival; PFS, progression-free survival.

###### 

NLR pooled HRs and 95% CIs in meta-analysis for OS and PFS

  Stratified analysis   OS   Begg's test *P*-value   PFS     Begg's test P-value                                                                                                                                                             
  --------------------- ---- ----------------------- ------- --------------------- ------------------- --------- ------------------- --------- ------- --- ------ ------- ------ ------------------- --------- ------------------- --------- ------
  Overall                                                                                                                                                                                                                                    
                        16   23.7                    0.07    37.7                  1.52 (1.41--1.63)   \<0.001   1.59 (1.42--1.77)   \<0.001   0.096   7   5.29   0.507   0      1.50 (1.21--1.85)   \<0.001   1.50 (1.21--1.85)   \<0.001   0.23
  Nation                                                                                                                                                                                                                                     
   Asian                3    0.43                    0.807   0                     2.43 (1.47--4.01)   0.001     2.43 (1.47--4.01)   0.001             2   0.31   0.577   0      1.99 (1.30--3.06)   0.002     1.99 (1.30--3.06)   0.002     
   Non- Asian           13   19.82                   0.071   39.5                  1.50 (1.40--1.62)   \<0.001   1.56 (1.39--1.74)   \<0.001           5   2.72   0.606   0      1.36 (1.07--1.74)   0.014     1.36 (1.07--1.74)   0.014     
  Treatment                                                                                                                                                                                                                                  
   First selected       13   16.97                   0.151   29.3                  1.49 (1.38--1.60)   \<0.001   1.53 (1.38--1.70)   \<0.001           5   5.14   0.273   22.2   1.51 (1.17--1.95)   0.002     1.55 (1.14--2.10)   0.005     
   Second selected      3    2.8                     0.247   28.5                  1.97 (1.51--2.57)   \<0.001   1.92 (1.37--2.69)   \<0.001           2   0.14   0.706   0      1.48 (1.01--2.17)   0.046     1.48 (1.01--2.17)   0.046     
  No. of patients                                                                                                                                                                                                                            
   \<182                7    1.04                    0.984   0                     2.16 (1.66--2.80)   \<0.001   2.16 (1.66--2.80)   \<0.001           6   5.18   0.394   3.4    1.52 (1.20--1.93)   \<0.001   1.53 (1.20--1.94)   0.001     
   ≥182                 9    15.15                   0.056   47.2                  1.47 (1/37--1.59)   \<0.001   1.50 (1.34--1.69)   \<0.001           1   --     --      --     1.38 (0.82--2.32)   0.225     1.38 (0.82--2.32)   0.225     
  Cutoff                                                                                                                                                                                                                                     
   \>3.3                7    10.68                   0.099   43.8                  1.58 (1.38--1.82)   \<0.001   1.72 (1.32--2.25)   \<0.001           4   0.73   0.867   0      1.87 (1.38--2.54)   \<0.001   1.87 (1.38--2.54)   \<0.001   
   ≤3.3                 9    12.52                   0.13    36.1                  1.49 (1.37--1.63)   \<0.001   1.56 (1.38--1.76)   \<0.001           3   0.41   0.814   0      1.20 (0.89--1.62)   0.233     1.20 (0.89--1.62)   0.233     

**Abbreviations:** NLR, neutrophil--lymphocyte ratio; OS, overall survival; PFS, progression-free survival.
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